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Abstract
Phage therapy is one of the most important control strategies envisaged for the
management of bacterial diseases in the aquatic environment. There are no other
effective alternative approaches for the natural control of bacterial diseases,
while phage therapy remains the best method which has not yet been exploited.
The occurrence, infectivity, lytic activities, therapeutic potentials, and efficacy of
the bacteriophages of Bacillus spp./Vibrio spp. for control of pathogenic bacteria
diseases such as Vibrio vulnificus, V. damsela, and V. furnissii in the cultures of
crustaceans are presented. An ideal method for long-term storage and recovery of
the lytic bacteriophages, agar bioassay method and one-step growth experiments,
in vivo and in vitro experiments, and validation of the usefulness of phage therapy
are described. The review highlights the occurrences of plagues of lytic phages of
Vibrio sp. and Bacillus spp. and their control effects of vibriosis both in vivo and
in vitro in the crustaceans, thus establishing the application and efficacy of the
phages of Vibrio/Bacillus against the pathogenic Vibrio spp. Development of
specific phage therapy or a cocktail of phages to a wide variety of systems is
considered to represent an interesting emerging alternative to antibiotic therapy
and vaccination.
Keywords: phage therapy, bacterial diseases, vibriosis, probiotics, bacteriophages,
antimicrobials, antibiotic resistance, crustaceans, shrimp, lobster, crab, Artemia
1. Introduction
1.1 Global crustacean production and losses due to diseases
Global fish production was 171 million tons estimated at USD 362 billion in 2016,
while aquaculture production was 80.37 million tons estimated at USD 232 billion
[1–3] consisting of 54.1 million tons of finfish production, 17.1 million tons of
molluscs, 7.9 million tons of crustaceans, and 938,500 tons of other aquatic animals
such as turtles, sea cucumbers, sea urchins, frogs, and edible jellyfish [3]. Freshwa-
ter finfish represents half of the global aquaculture production (54%), molluscs
being the second more produced aquaculture item in the world (24%) [2]. Crusta-
ceans come next in production relevance, represented mostly by penaeid shrimps
and grapsid crabs [2, 3]. Aquaculture is the world’s fastest growing segment with a
global increase of 5.7% per annum in shrimp production resulting in an increase of
18% by 2020, and the estimated world production of farmed shrimp is 3.5 million
metric tons though the diseases, international market prices, and production costs
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are the main challenges and constrains to the growth and productivity of the shrimp
industry on a global level [4]. However, disease outbreaks have caused serious
economic losses in several countries, and the estimated global losses due to shrimp
diseases are around US$ 6 billion per annum [5, 6]. Such concerns confirm that the
bacterial diseases are the most important contracting factors for development of
the global aquaculture industry [7].
1.2 Bacterial diseases in crustaceans
Bacteria in the aquatic environment and the bacterial diseases, viz. vibriosis,
shell diseases (chitinolytic bacteria), and gaffkemia of lobsters, are ubiquitous and
are significant for the survival of crustaceans in confined habitats [8–22]. Diseases,
Diseases Hosts Causative bacterial species
Vibriosis Penaeus monodon, P. merguiensis,
and P. indicus (eggs, larvae,
postlarvae, juveniles, and
adults); Litopenaeus vannamei,
Macrobrachium, lobster
Homarus americanus, crab
Portunus trituberculatus
Vibrio harveyi, V. splendidus;
Vibrio harveyi, V. alginolyticus,
V. parahaemolyticus, V. anguillarum,
V. furnissii, V. mimicus, V. damsela
[7, 13–22]
Bacterial fouling of surfaces
with filamentous bacterial
disease
Penaeus monodon, P. merguiensis,
P. indicus
Leucothrix sp.,Thiothrix sp.,
Flexibacter sp., Cytophaga sp.,
Flavobacterium sp. [7]
Shell disease, brown/black
spot, black gill, black rot/
erosion, blisters, necrosis of
appendages
Crabs and shrimp, white and
brown shrimp Penaeus monodon,
P. merguiensis, P. indicus
Chitonoclastic bacteria Vibrio spp.
infections Vibrio, Aeromonas,
Pseudomonas, Flavobacterium [7, 8, 11]
Chitinolytic bacterial
disease, shell disease, box
burnt disease, bacterial shell
disease
Cancer spp., Callinectes sapidus,
other crabs; lobsters, shrimps,
and crayfish
Chitinolytic or chitinoclastic bacteria
(Gram-negative), viz. Vibrio spp.,
Pseudomonas spp., and Aeromonas spp.
[7, 9–11, 13, 17, 20–22]
Milky hemolymph disease
(milky hemolymph
syndrome [MHS])
Spiny lobster Panulirus spp.,
Panulirus ornatus, P. homarus,
and P. stimpsoni; Litopenaeus
vannamei (Penaeus monodon,
Carcinus maenas)
Rickettsia-like bacterium, a-
Proteobacteria, Streptococcus sp.,
[7, 10–12]
Gaffkemia, septicemia Lobsters Homarus americanus Gaffkya homari [7, 9–11]
Bacteremias Bacterial diseases of crabs Vibrio, Aeromonas, Rhodobacteriales-
like organism, Vibrio cholerae, Vibrio
vulnificus, chitinoclastic bacteria,
Rickettsia intracellular organisms,
chlamydia-like organism,
Spiroplasma, chitinoclastic bacteria,
Rickettsia intracellular organisms,
chlamydia-like organism, and
Spiroplasma [7]
Fungal diseases Penaeus monodon, [larval
(nauplii, zoea, and mysis)
Indian tiger prawn]
Macrobrachium rosenbergii
Lagenidium callinectes [16, 17]
Table 1.
Bacterial diseases, causative organisms, and their crustacean hosts.
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causative organisms, and their crustacean hosts are listed in Table 1. Gaffkemia of
lobsters is caused by Aerococcus viridans var. homari and is the root cause of mass
mortalities of lobsters, while crabs, viz. Cancer borealis and C. irroratus, serve as
reservoir hosts of Aerococcus viridans [8–13]. Vibriosis causes mass mortalities in
several crustaceans such as penaeid shrimp Penaeus monodon and P. japonicus, fresh
water prawnMacrobrachium, lobster Homarus americanus, blue crabs Callinectes
sapidus, rock crabs Cancer irroratus, and shore crab Carcinus maenas. Shell diseases
are caused by chitinolytic bacteria which were encountered in English prawn
Palaemon serratus; American lobsters Homarus americanus; penaeid shrimp; king
crabs, Paralithodes camtschaticus and Paralithodes platypus; and tanner crabs
Chionoecetes tanneri, and these crustaceans are affected by rust diseases which are
caused by chitin-destroying bacteria [8–22]. Significant mortalities of larval, post-
larval, and adult crustaceans, viz. shrimp Penaeus monodon, Litopenaeus vannamei,
andMacrobrachium, lobster Homarus americanus, and crab Portunus trituberculatus,
are caused by common pathogens such as Vibrio harveyi, V. alginolyticus, V.
parahaemolyticus, V. anguillarum, V. furnissii, V. mimicus, V. damsela, Pseudomonas,
and Aeromonas [9–22]. Infectious diseases caused by Vibrio species represent the
greatest challenges that cause vibriosis with considerable economic losses, and that
is the most overwhelming problem in aquaculture, shrimp, and crustaceans [7–101].
2. Phage therapy
Phage therapy is a prospective ideal therapy for vibriosis in aquaculture of
crustaceans. Bacteriophages are defined as bacterial viruses that can infect cells,
multiply in, cytolyse, and destroy susceptible bacteria. Bacteriophages are viruses of
bacteria which have a natural ability to target, infect, and destroy their host cells
of a particular bacterial species or groups or even unrelated bacteria, and thus they
play a major role in controlling their target bacterial population density in nature
[23–60]. They are both omnipresent and copious in the aquaculture environment,
especially in seawater, in which the total numbers of viruses normally surpass the
bacterial cell concentration by a factor of 10 [25]. “Most phages reproduce upon
entering a cell and in that process kill their host. They encode two families of
proteins, holins, and lysins, which allow the phage progeny to burst through the
bacterial cell wall and go off in search of new hosts. But the cell is already dead by
the time that happens in terms of lethality; the lysis is just a matter of burning down
the house for good measure.” An estimated 108 strains of phage with approximately
1031–1032 phages are known to occur in the biosphere at any given time [23].
Bacteriophages are used for the isolation and identification of specific bacteria to
help in the diagnosis of the bacterial diseases, to kill antibiotic-resistant, virulent
bacteria through a natural phenomenon called lysogeny, whereby one of the phage-
infected bacteria in a colony kills another uninfected bacterium through phage
missiles or antibacterial peptides [24, 25, 36–39, 41].
2.1 Phage therapy, an alternative to antibiotics
Due to their specific antibacterial activities and significance of the phage therapy
as an alternative to antibiotics, bacteriophage therapy is re-emerging, and conse-
quently this has become a potentially novel and useful concept to kill even intracel-
lular pathogenic bacteria and warrant future development. Bacteriophage therapy
has been extended from medical applications into the fields of agriculture, aqua-
culture, and the food industry [28–30, 39]. Bacteriophages specific for Vibrio spp.
have been described [36–41]. Bacteriophages are known to infect >140 bacterial
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genera, and they are the most valuable and ubiquitous (1031) phage organisms in
the world [26–35, 40–45]. Earliest description of phages and their antibacterial
activity has been independently demonstrated [62]. D’Herelle [33] published a
comprehensive account of phages, and hence the International Bacteriophage Insti-
tute was established in Tbilisi, Georgia, in 1923, now called as “the George Eliava
Institute of Bacteriophages, Microbiology and Virology” [32, 34], which is still
involved in researching phage therapy applications and supplies phage for the
treatment of various bacterial infections. D’Herelle’s first phage therapy experi-
ments against bacterial dysentery were exceptionally successful and were very
promising in the removal of the infectious organisms [32, 34]. However some of the
results of the early phage therapy experiments of infectious host organisms were
known to be contradictory with reports of both success and failure. Whenever
failures occurred in phage therapy, they were attributed to a range of factors. They
include unsatisfactory understanding of phage biology, inadequate experimental
technical knowledge, poor quality of phage preparations, and a lack of understand-
ing of the causes of illness being treated. The discovery of such specific bacterio-
phages were at first considered to become powerful beneficial therapeutic agents
against pathogenic microorganisms but could not be put into practice because of the
dawn of antibiotic era experiencing overuse/misuse of antibacterial medication that
resulted in the development of untreatable antibiotic resistance [32, 36]. Commer-
cialization of antibiotics in the Western countries in the 1940s had led to a simulta-
neous decline in the use of phages as human therapeutics, while in some of the
Eastern European countries, exploitation of phage therapy was continued either
alone or in combination with antibiotics [19, 34, 61–73]. The experimental phage
therapy could be an alternative to antibiotics and replace them when they fail for
the treatment of chronic infections, and such a successful eradication of drug-
resistant bacteria was documented [19, 42, 61–73]. Moreover, the significantly
decline costs of phage therapy constitute an important additional battle for its wider
application in the current era of a worldwide circumstance in antibiotic resistance.
The efficacy of phage therapy is well recognized and demonstrated in a few cases
[32, 64–66]. Even a single dose of phage was reported to be much more effective
than multiple doses of antibiotics such as ampicillin, tetracycline, and chloram-
phenicol [66]. The use of phage therapy to control fish pathogens has also been
reported [23, 24, 42, 43]. Phage lysins have been used as potential therapeutics for
treatment of bacterial infections [44]. Furthermore, the US Food and Drug Admin-
istration has approved commercial phage preparations to prevent bacterial contam-
inations. Such developments have prompted to explore the possibilities of using
bacteriophages to control bacterial infections in crustacean aquaculture [36–41].
Further cautious phage collection and perfect experimental conditions for phage
propagation and purification, route and timing of phage administration, and envi-
ronmental monitoring of phage for use are needed. Such a focus may help in further
development of probiotics, phage therapy applicable to a wide variety of systems,
which is considered to signify an emerging alternative to antibiotic therapy and
vaccination.
2.2 Probiotics in crustacean cultures
Probiotics are defined as applications of whole or components of microorgan-
isms or “a live microbial adjunct which has a beneficial effect on the host by
modifying the host-associated or ambient microbial community, by ensuring
improved use of the feed or enhancing its nutritional value, by enhancing the host
response towards disease, or by improving the quality of its ambient environment”
[74–93]. A probiotic is a live microbial feed supplement which benefits the host
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animal by improving its intestinal microbial balance [82]. Lactic acid bacterium
Bacillus S11 was tested as probiotics and has been proven as antagonists of shrimp
pathogens [75]. Bacillus spores were used as biocontrol agents to reduce Vibrio
species in shrimp culture facilities [83]. The inhibitory activity of Bacillus subtilis
BT23, isolated from shrimp culture ponds, is against pathogenic Vibrio harveyi
under in vitro and in vivo conditions [39, 73]. The concept of probiotics is exploited
to “augment” naturally occurring pathogenic bacterial population to increase the
growth rate and control diseases of organisms in aquaculture such as fish/shellfish
[84, 85]. Several microorganisms have been evaluated as probiotics which have
been shown to be successful in the larval stages of the aquatic organisms in
preventing the diseases, improving digestion and growth [82, 84, 87]. Some of the
proposed mechanisms that provide protection against pathogens involve the pro-
duction of inhibitory compounds, competition for essential nutrients and adhesion
sites, enhancement of disease resistance, and modulation of host immune responses
[82, 87]. A probiotic containing a combination of several different bacteria has
been shown to be more efficient at controlling bacterial pathogens [82, 90, 91].
Probiotics are known to act and inhibit the growth and proliferation of bacterial
pathogens both in vivo and in vitro by generating antibacterial compounds such as
bacteriocin, siderophores, lysozymes, proteases, hydrogen peroxide, antibiotics,
and organic acids [91]. In aquaculture, some microorganisms are more beneficial to
host organisms in reducing the incidence of diseases though the factors and mech-
anisms which mediate the benefits to the host are poorly understood. Future studies
should be focused on evaluating the mechanisms by which the probiotics interact
with the host and pathogens and their biology.
2.3 Proprobiotics
Proprobiotic is defined as a synbiotic comprising pre- and probiotics involving a
combination of strains of nonpathogenic bacteria and yeast so as to provide supple-
mentary nutrients and to protect against invading pathogens. Commercially avail-
able proprobiotics are known to competitively exclude the potential pathogen
through the use of proprobiotics in aquaculture. Effects of Ergosan and Vibromax
are used to prevent vibriosis in Litopenaeus vannamei [42, 43]. Probiotics (e.g.,
Arda-Tek, Australia, viz. DMS1000, S-1100, DMS-2001, DMS-2002, DMS-2004,
etc., Wunapuo-15 of Team Aqua Corporation) are used to reduce the number of
Gram-negative pathogenic bacteria including Vibrio in the water and to maintain
stable water quality, to stabilize plankton, to reduce rate of sludge buildup on the
pond bottom, and to digest microbial slime [73, 82, 84–91]. To assess the actual
impact of these probiotic products in the field, it is fundamental to determine the
efficacy of the probiotics and the continuance of their application. The potency of
the probiotic products against selected pathogenic bacteria (and viruses) also needs
to be critically evaluated. The application of some beneficial bacteria has been an
option in aquaculture to achieve a number of benefits, viz. to reduce mortality in
shrimp, to enhance production and increase harvest yield and eliminate antibiotic
use, and to enhance immunity and disease resistance in black tiger shrimp Penaeus
monodon by a probiont bacterium (Bacillus S11) [84–91]. Immunity enhancement
occurs in black tiger shrimp Penaeus monodon by a probiont bacterium (Bacillus
S11), and the immune stimulator capacity of probiotics may be affected by factors
such as source, type, dose, and duration of supplementation [80, 85]. The use of
probiotic mixtures consisting of Bacillus tequilensis and B. endophyticus along with
commercial probiotics was shown to be beneficial in altering the bacterial commu-
nity of larval shrimp Litopenaeus vannamei when the hosts were challenged with
Vibrio parahaemolyticus. Similarly application of Bacillus sp. promoted cellular and
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humoral immune resistances and provided disease protection in tiger shrimp P.
monodon. The effects of probiotics such as Bacillus cereus, Paenibacillus polymyxa,
and Pseudomonas sp. PS-102 as biocontrol agents against pathogens of various Vibrio
species in shrimp were evaluated. Growth promoter probiotics have been used in
aquaculture to enhance the growth of cultivated species, whereas their side effects if
any on the host need to be investigated. The probiotics was shown to increase the
survival and growth of white shrimp (Litopenaeus vannamei), and the production
increased by 35%, whereas with the use of antimicrobials, it decreased by 94% and
thus demonstrated the significance of endemic Bacillus probiotics on the improve-
ment of the health of larval shrimp [71, 73]. The efficacy of the non-hemolytic
probiotic Bacillus strains against pathogenic Vibrio species, viz. Vibrio campbellii,
V. vulnificus, V. parahaemolyticus, and V. alginolyticus on the growth of the larval
shrimp was tested by using a daily concentration of 1  105 cfu ml1 with initial
bioassay density of 225 nauplii L1, and the treatments promoted a considerable
increase in survival and growth of the larval shrimp compared to the control, and
thus the study has established a significant antagonistic activity of the probiotic
Bacillus strains against the Vibrio species [48]. Various strains of Bacillus, or a
commercial product made from Bacillus sp., Saccharomyces cerevisiae, Nitrosomonas
sp., and Nitrobacter sp., used as probiotics show prevention of infection and pro-
motion of growth rate of all the stages of the white shrimp Litopenaeus vannamei
Boone and Fenneropenaeus indicus when the diet was supplemented with 50 g of
probiotic kg1 of food. The use of probiotic Shewanella algae in shrimp farms is
found to be safe for the consumer of shrimp [92]. A scientific rational approach for
the evaluation of aquaculture probiotics and guidelines is needed for their use and
safety.
2.4 Bacillus for the control of vibriosis
Pathogenic Vibrio spp. were controlled by cell-free extracts of Bacillus under
in vitro and in vivo conditions indicating that probiotic treatment offers a promising
alternative to the use of antibiotics in shrimp aquaculture [41, 63, 70, 85]. Though
probiotic bacteria are currently used to improve the health of the shrimp ponds and
increase productivity and reduce mortality of prawns, little attention has been paid
to bacteriophages preying on the probiotic bacteria of crustacean culture such as
Vibrio/Bacillus spp. from aquaculture systems. A special focus needs to be given to
bacteriophages infecting probiotic bacteria to explore the antibacterial potential of
bacteriophages of Bacillus spp., Vibrio spp., and other bacteria. The existence of
bacteriophages in the probiotic Bacillus sp. and Vibrio spp. controlling the infectiv-
ity of the Vibrio spp. with a significant reduction in the mortality of infected shrimp
was demonstrated [37, 41]. Anti-Vibrio activities of Bacillus spp. mainly due to the
production of bacteriocin or bacteriocin-like substances have been reported from
B. subtilis, B. megaterium, B. stearothermophilus, B. licheniformis, B. thuringiensis,
B. thermovorans, and B. cereus [16, 22, 45, 47, 68, 69, 83]. P. monodon larvae fed with
Bacillus S11 showed 100% survival after challenge with pathogenic V. harveyi,
whereas only 26% control animals survived.
2.5 Antimicrobials
Vibrio species are Gram-negative curved rod-shaped bacteria that belong to the
Vibrionaceae family, and they naturally inhabit the estuarine, coastal, and marine
environment worldwide. Vibrio species occur as the dominant flora in all develop-
mental stages of Penaeus monodon, and they have been described as the causal
pathogens. Vibriosis is a severe bacterial disease in penaeid shrimp and is responsible
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for large-scale losses in the aquaculture industry, leading to prophylactic as well as
therapeutic use of antimicrobials [18–22, 70–73]. Antibiotics are used in shrimp
farming to control or treat bacterial disease outbreaks with an expected 100,000–
200,000 tons of antibiotics being consumed in the world every year [57]. Oxytet-
racycline, tetracycline, quinolones, sulfonamides, and trimethoprim are among the
antimicrobials utilized to control bacterial infections in the aquaculture industry.
Indiscriminate prophylactic uses of diverse antibiotics in the shrimp hatcheries/
farms have resulted in antibiotic resistance of the bacteria causing mass mortalities
of the hosts [73–75]. The potential negative consequences are the development of
drug-resistant bacteria and reduced efficacy of antibiotic treatment. Shrimp
farmers are exceedingly dependent on various antibiotics as a preventive measure
against shrimp bacterial infections with 14% of farmers using antibiotics on a daily
basis in their farms [22].
2.6 Antibiotic-resistant bacterial infections in crustaceans
All of the 121 isolates of Vibrio spp. were found to be 100% resistant to ampicil-
lin, cloxacillin, oxacillin, erythromycin, vancomycin, penicillin G, and furazolidone
and partially resistant to cefaclor, streptomycin, rifampicin, oxytetracycline,
nalidixic acid, cefotaxime, and chlorotetracycline [14, 16]. Molitoris et al. [14]
reported a high degree of resistance to ampicillin and furazolidone, and incidence of
resistance to chloramphenicol, neomycin, and gentamycin has also been detected
[16, 18–20, 22, 46, 69]. Multidrug-resistant Vibrio harveyi isolated from black gill-
diseased Fenneropenaeus indicus and antibacterial activity against pathogenic Vibrio
harveyi and its protective efficacy on juvenile F. indicus were reported. In vitro
susceptibility of antibiotics against Vibrio spp. and Aeromonas spp. isolated from
Penaeus monodon hatcheries and ponds and the effect of probiotics, antibiotics, and
pathogenicity of Listonella anguillarum-like bacteria isolated from Penaeus monodon
culture systems and antibiotic-resistant Vibrio spp. were commonly isolated from
hatchery-reared postlarvae compared to farm-reared P. monodon [61, 62, 72, 73,
79, 85]. The unrelenting use of antibiotics against diseases in human beings and
other life forms may pollute the aquatic system, and their impact on developing
antibiotic-resistant Vibrio sp. may be a serious threat in addition to the use of
antibiotics in aquaculture farms [63, 70]. Control of the bacterial diseases depends
on improvement of management practices to minimize the risk of introduction of
infectious agents into aquaculture systems and to reduce predisposing factors such
as overcrowding and overfeeding.
2.7 Antibiotic-resistant genes (ARGs)
A study assessed a variety of antibiotic-resistant bacteria and detected the pres-
ence of their resistance genes from mariculture environments. A variety of antibi-
otics that were used in aquaculture have led to the occurrence of antibiotic-resistant
genes in bacteria, and in these bacteria many different ARGs can be found, and they
are β-lactam- and penicillin-resistant genes penA and blaTEM-1; chloramphenicol-
resistant genes catI, catII, catIII, catIV, and floR; tetracycline-resistant genes tatA,
tatB, tatC, tatD, tatE, tatG, tatH, tatJ, tatY, and tatZ; and many more [65, 68]. ARGs
can be transferred among bacteria via conjugation, transduction, or transformation.
The widespread emergence of antimicrobial resistant bacteria worldwide has
become a major therapeutic challenge. Therefore there is a need for development of
novel non-antibiotic approach such as phage therapy biocontrol agents to fight
against resistant bacterial infections due to the shortage of new antibiotics in devel-
opmental pipeline [19, 61–73]. Thiel [25] stated that phage therapy is “a nearly
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forgotten therapy that may yet re-emerge as a savior to this accelerating crisis of
antibiotic resistance. For every bacterium known on this planet, there are legions of
bacteriophages—tiny viruses that seek out bacteria and use them as a breeding
ground, almost invariably destroying their prokaryotic host in the process. That
makes them harmless to even to nontarget bacteria—distinguishing them from
broadspectrum antibiotics, which, when they work, can wipe out beneficial flora
along with a troublesome infection.” The phage specificity has its drawbacks as
there is a requirement of the right match between phage and bacteria which needs
to be determined for the phage therapy to work. There has been renewed concern in
the application of bacteriophage as a non-antibiotic approach to control bacterial
infections in various fields including human infections, food safety, agriculture, and
veterinary applications. However the guideline data on the use of phage therapy
applied to invertebrates, like shrimp and other crustaceans, are nonexistent
[64, 68, 92, 93].
2.8 Bacteriophage therapy for biocontrol of vibriosis in crustaceans
A bacteriophage isolated from a shrimp hatchery was shown to infect V. harveyi,
signifying its potential as a biocontrol agent of luminous vibriosis. In vitro treat-
ments of bacteriophages were shown to exhibit a significant reduction (2–3 log
units) in the number of V. harveyi host cells [41, 46, 48, 49]. These studies showed
that bacteriophages could be used for biocontrol of V. harveyi and that bacterio-
phage therapy could be effective as an alternative to antibiotics in the control of
luminous vibriosis in shrimp hatchery systems [23–69]. In vitro experiments con-
firmed that bacteriophages could be effectively used in vivo as biological agents to
control Vibrio sp. in aquaculture systems [36–39, 41, 46, 48, 49]. Investigation on
the occurrences of luminescent V. harveyi and their bacteriophages in shrimp
showed that the presence of low concentrations of bacteriophages in the larval
rearing tank waters could not prevent the development of luminous vibriosis
[46–49], and this study showed that the presence of optimal concentration of phages
is required for effective reduction of the pathogenic bacteria. A lytic spectrum of
bacteriophages (Viha1, Viha2, Viha3, Viha4, Viha6, Viha7) occurring in nature
exhibited a wide spectrum of activity against V. harveyi, suggesting their potential
as agents for biocontrol of vibriosis in aquaculture environments [51]. A lytic phage
(PW2) was isolated and characterized under controlled conditions in the laboratory
from the host bacterium V. harveyi CS101 [49], and the useful bacteriophages for
the biocontrol of vibriosis have been explored. A probiotic strain V. alginolyticus
reduced the diseases and mortality of infected P. monodon with A. salmonicida,
V. anguillarum, and V. ordalli [49]. A soil bacterial strain, PM-4, was shown to
exhibit in vitro inhibitory effect against V. anguillarum and to promote the growth
of P. monodon nauplius [53]. Inoculation of Bacillus S11, a saprophytic strain,
resulted in greater survival of the post-larval P. monodon that were challenged with
pathogenic luminescent bacterial culture [51]. These works strongly suggest an
effective control of microflora in crustaceans can be achieved in aquaculture
environments by bacteriophage-producing bacteria. The crustacean host, causative
agent, diseases, and source of bacteriophages/bacteria are listed in Table 2.
2.9 In vitro and in vivo effects of Bacillus against vibriosis in shrimp
In vitro and in vivo antagonistic effects of Bacillus against the pathogenic Vibrio
species were evaluated [40]. Cell-free extracts of Bacillus subtilis BT23 were shown
to exhibit inhibitory effects against the growth and proliferation of Vibrio harveyi
isolated from black gill-diseased Penaeus monodon. The probiotic effect of Bacillus
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Crustacean
host
Bacterial agent Infection/
disease
Bacteriophage Source of the
bacteriophage
Efficacy of bacteriophage Outcome of the phage therapy References
Shrimp larvae
Penaeus
monodon
Vibrio harveyi Luminous
vibriosis
Myoviridae (VHLM) Extracted from a
toxin-producing
strain of V. harveyi
isolated from
moribund prawn
Vibriolysis VHML showed a narrow host
range with a preference for
V. harveyi rather than 63 other
Vibrio isolates and 10 other
genera
[100]
Shrimp larvae
Penaeus
monodon
Vibrio harveyi Luminous
vibriosis
Siphoviridae Shrimp farm waters
from the West coast
of India
18-day-old PL shrimp were
challenged with the bacteria (105
cells ml1, laboratory trial: (1)
bacteriophage suspension
(109 pfu ml1) was added
initially; after 24 h (another
0.1 ml), (2) only once initially
with 0.1 ml of the phage
suspension; (3) no addition.
Hatchery trial (1) treatment with
bacteriophage (109 pfu ml1) at
the rate of 200 ppm daily so that
phage concentration in the water
was 29–105 pfu ml1; (2)
treatment with antibiotics
(oxytetracycline 5 ppm,
kanamycin 10 ppm daily); (3) no
treatment
Enhanced survival (80%) of
P. monodon larvae on treatment
with two doses of bacteriophage
when compared with the control
(25%). Hatchery trial: survival in
the control tank was only 17%,
while in antibiotic-treated tanks,
survival was 40%; in the
bacteriophage-treated tank,
survival was 86%. Bacteriophage
therapy has an excellent potential
in management of luminous
vibriosis in aquaculture systems
[48]
Larval shrimp
Penaeus
monodon
Vibrio harveyi Luminous
vibriosis
Siphoviridae Three from oyster
tissue and one from
shrimp hatchery
water
Hatchery tanks, with post-larval
five-stage larvae, presenting
luminescence and mortality,
were used. Bacteriophage
treatment (two tanks): one
suspension (29 106 pfu ml1) was
added by day following the
order: Viha10, Viha8, Viha10,
and Viha8 chemotherapy (two
Bacteriophage treatment resulted
in over 85% survival of Penaeus
monodon larvae. The normal
hatchery practice of antibiotic
treatment resulted in a survival
range from 65 to 68%.
This study shows that
bacteriophages could be used for
biocontrol of V. harveyi
[46]
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tanks): oxytetracycline
(5 mg L1), kanamycin
(10 mg L1)
Penaeid shrimp
P. monodon
Vibrio harveyi Luminous
vibriosis
Seven
bacteriophages
specific to Vibrio
harveyi (Viha1 to
Viha7), six from
Siphoviridae and
one Myoviridae
(Viha4)
Coastal aquaculture
systems like shrimp
farms, hatcheries,
and tidal creeks
along the East and
West coast of India
All the phages were found to be
highly lytic for V. harveyi. The
phages exhibited a different lytic
spectrum for a large number of
bacterial isolates tested. Three of
the phages (Viha1, Viha3, and
Viha7) caused 65% of the strains
to lyse, while Viha2, Viha4, and
Viha6 caused 40% of the host
strains to lyse. Only Viha5 had a
narrow spectrum (14%). Six of
the seven phages isolated had a
broad lytic spectrum and could
be potential candidates for
biocontrol of V. harveyi in
aquaculture
[51]
Shrimp
P. monodon
Vibrio harveyi Luminous
vibriosis
Siphoviridae (VH1
to VH8)
Shrimp farm In vitro experiment All the isolates of bacteriophage
(VH1–VH8) caused lysis of the
host bacterial cells within 2 h.
The propagation curve for each
phage showed a burst time from
1 to 10 h. Bacteriophages of
Vibrio sp. shall be effectively
used in vivo as biological agents
to control these pathogenic
bacteria in aquaculture systems
[39]
Shrimp
P. monodon
Vibrio harveyi
CS101
Luminous
vibriosis
Siphoviridae (phage
PW2)
Shrimp pond water Phage adsorption rate increased
rapidly in the first 15 min of
[52]
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infection to 80% and continued
to increase to 90% within 30 min
of infection. The stability of
phage PW2 was dependent on
temperature and pH. It was
inactivated by heating at 90°C
for 30 min and by treating at pH
2, 3, 11, and 12. One-step growth
curve and latent and burst
periods were 30 and 120 min,
respectively, with a burst size of
78 pfu per infected center. Six
structural proteins were detected
Larval shrimp
P. monodon
V. harveyi Luminous
vibriosis
ϕH17-5c, ϕH17-7b,
ϕH17-8b, and
ϕH17-9b
Secluded from
shrimp farm water
from the West coast
of India and
demonstrated to
exhibit a broad lytic
activity against
V. harveyi isolates
In a set of laboratory
experiments, post-larval Penaeus
monodon was exposed to
106 cfu ml1 cells of Vibrio
harveyi and was treated with
100 ppm phage which has led to
a drastic reduction of Vibrio
harveyi counts with 86% survival
of the infected larvae, while the
survival of the phage-untreated
larvae was 25%
In the antibiotic (oxytetracycline
5 ppm, kanamycin 100 ppm/
day)-treated hatchery tanks, an
initial reduction of luminous
bacterial counts were shown, and
after 48 h the bacterial count
increased to 106 ml1 showing
the luminous vibriosis and
mortality of the nauplii of
Penaeus monodon with 40% larval
survival. In contrast, in the
bacteriophage-treated tank, the
larval survival was 86%, and the
survival rate in the control tank
was only 17%
[48, 49]
Shrimp,
P. monodon
V. vulnificus Vibriosis Phages VV1, VV2,
VV3, and VV4 from
V. vulnificus
VV1, VV2, VV3, and
VV4 phages were
detected from
In vitro experiments show
successful potential phage
therapy; lytic V. vulnificus phages
V. vulnificus phages exhibited a
broad lytic spectrum and
potential biocontrol of luminous
[36–39]
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shrimp aquaculture
system
infect a wide variety of other
Vibrio spp./isolates
vibriosis in the shrimp
aquaculture system
Phyllosoma
larvae of the
tropical rock
lobster
Panulirus
ornatus
V. harveyi Luminous
vibriosis
Six bacteriophages
from Siphoviridae
(VhCCS-01,
VhCCS-02, VhCCS-
04, VhCCS-06,
VhCCS-17, and
VhCCS-20) and two
from Myoviridae
(VhCCS-19 and
VhCCS-21)
Isolated from an
epizootic in
aquaculture-reared
larval phyllosomas
of the ornate spiny
lobster Panulirus
ornatus water
samples from
discharge channels
and grow-out ponds
of a prawn farm
Exhibited a clear lytic activity
against V. harveyi
(1) Addition of phage VhCCS-06
(1 ml) 2 h after inoculation; (2)
addition of phage VhCCS-06
(1 ml) 6 h after
Bacteria-free supernatants were
obtained by centrifugation at
10,000 g for 15 min and by
filtration of the aliquots of the
enriched water samples;
supernatants (10 ll) were
inoculated onto NAMS plates,
grown at 28°C for 24 h, and the
bacteria-free supernatants were
stored at 4°C
Exhibited a clear lytic activity
against V. harveyi with no
apparent transducing properties.
Phages of VhCCS-19 and VhCCS-
21 areMyoviridae
bacteriophages and lysogenic and
induce bacteriocin production
in the host bacteria (V. harveyi
strain 12); Siphoviridae phage
(VhCCS-06) delayed the entry of
a broth culture of V. harveyi
strain 12 into exponential
growth, though it could not
prevent the overall growth of the
bacterial strain. This effect was
due to the multiplication of
phage-resistant cells of
V. harveyi. Phage resistance is an
obstacle to the use of phage as
therapeutic agents. The isolated
phages exhibited lytic activity
against strains of V. harveyi, a
primary pathogen of phyllosoma
of the tropical rock lobster,
P. ornatus. These phages can be
used as a biocontrol agent to
combat vibriosis in the rearing
[55]
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system of phyllosoma of the
tropical rock lobster, P. ornatus
Live prey
Artemia salina
V. alginolyticus
strain V1
Vibriosis Two novel
bacteriophages φSt2
and φGrn1
Vibrio alginolyticus
strain V1, isolated
during a vibriosis
outbreak in cultured
seabream
In vitro cell lysis experiments
against the bacterial host V.
alginolyticus strain V1 and also
against 12 Vibrio strains
originating from live prey
Artemia salina cultures, viz. V.
anguillarum, V. harveyi, V.
alginolyticus, V. ordalii, V.
parahaemolyticus, V. splendidus,
and V. owensii). It indicated a
strong lytic efficacy of the 2
phages
In vivo administration of the
phage cocktail consisting of φSt2
and φGrn1, directly on live prey
A. salina cultures, has led to a
93% decrease of Vibrio
population, viz. V. anguillarum,
V. harveyi, V. alginolyticus,
V. ordalii, V. parahaemolyticus,
V. splendidus, and V. owensii,
after 4 h of treatment
[98, 99]
Brine shrimp
nauplii Artemia
franciscana
V. parahaemolyticus Vibriosis of
Artemia
franciscana
VPMS1 phage VPMS1 is a lytic
phage of Vibrio
parahaemolyticus,
isolated from a
marine clam
V. parahaemolyticus-infected
brine shrimp nauplii were treated
with a single dosage of VPMS1
phage, which was effective
enough to eliminate the adverse
effects of V. parahaemolyticus in
brine shrimp. Efficacy was not
affected by the reduction in the
dosage
The phage therapy was
successful in preventing
vibriosis; a single dosage of
VPMS1 phage was effective
enough to get rid of the adverse
effects of V. parahaemolyticus in
brine shrimp; the beneficial
effects of the therapy were
compromised if the application
of phages was delayed
[97]
Penaeus
monodon rearing
waters in
shrimp ponds in
Palk Strait,
South East coast
of India
Vibrio
parahaemolyticus
Vibrio
parahaemolyticus
and its potential
lytic phage from
Penaeus monodon
Lytic phage (VVP1)
belongs to the
Myoviridae family
Lytic phage (VVP1)
able to infect strains
of N1A and N7A,
V. parahaemolyticus,
and strains of N3B
and N13B Vibrio
alginolyticus
One-step growth experiments,
multiplication and host range,
and pH and temperature stability
of the lytic phage (VVP1) were
shown; the phage showed
protective biocontrol effects in
reducing the pathogenic V.
P. monodon larvae infected with
V. parahaemolyticus showed
enhanced survival of the larvae
in the presence of phage
treatment at lytic phage (VVP1),
2.3  1010 PFU ml1, when
compared with the control and
[101]
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parahaemolyticus in infected
shrimp larvae
showed that the application of
phage therapy is a useful strategy
to prevent and eliminate or
reduce shrimp pathogenic
V. parahaemolyticus in the
aquaculture system
V. alginolyticus
phages were
isolated from
seawater
samples after
enrichment
V. alginolyticus,
Vibrio alginolyticus,
a zoonotic
pathogen that
causes mass
mortality in
aquatic animals
and infects humans
Vibriosis, a
zoonotic
pathogen causing
mass mortality in
aquatic animals
and infecting
humans
Phage pVa-21,
Myoviridae
Phage pVa-21 infects
bacteria belonging
to the family
Vibrionaceae, viz. V.
alginolyticus and V.
harveyi, and could
not infect
V. parahaemolyticus,
V. anguillarum,
V. campbellii, and
V. vulnificus
Bacteriophage pVa-21 belongs to
Myoviridae, characterized as a
candidate biocontrol agent
against V. alginolyticus. It exhibits
planktonic or biofilm lytic
activity and showed stability
under various conditions. It has
latent period and burst size
approximately 70 min and 58
plaque-forming units/cell,
respectively. Phage pVa-21 can
inhibit bacterial growth in both
the planktonic and biofilm states.
The phage is related to the giant
phiKZ-like phages, classified as a
new member of the phiKZ-like
bacteriophages that infect
bacteria belonging to the family
Vibrionaceae
Infect bacteria, viz. V.
alginolyticus and V. harveyi in
both the planktonic and biofilm
states
[101]
Table 2.
Crustacean host, bacteria, disease, and source of bacteriophages/bacteria for bacteriotherapy.
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was tested by exposing shrimp to B. subtilis BT23 at a density of 106/108 cfu ml1 for
6 days before a challenge with V. harveyi at 103/104 cfu ml1 for 1 h infection
(Figure 1a-f). Probiotic treatment of B. subtilis BT23 showed a 90% reduction in
accumulated mortality of P. monodon. Pathogenic Vibrio species were controlled by
Bacillus under in vitro and in vivo conditions, and the results indicated that probiotic
treatment offers a promising alternative to the use of antibiotics in shrimp aquacul-
ture.
The occurrence of phages in infected cells of Bacillus sp. is illustrated
(Figure 1a-c). Each bacteriophage particle of the bacterium Bacillus sp. presented as
electron-dense objects comprising a distinctive head with a flexible noncontractile
tail. The preparations consisted of 30 min–2 h exposures of Bacillus cells to in vitro
phage infection, and the TEM of such experimentally phage-infected cells showed
actively adsorbing and infecting phages onto the surface of bacterial cell membrane
(Figure 1b), while phage particles occurred within the completely lysed cells in
8–24 h (Figure 1c).
TEM analysis of the phages of Vibrio host cells showed the occurrence of tailless
phages with a double-layer membrane covering the icosahedral head. Phage-
uninfected, phage-infected, and completely lysed Vibrio cells are shown
(Figure 1d–f).
2.10 Antagonism of Bacillus against Vibrio spp.
An antagonism assay consisting of cell-free extract of Bacillus BT21, Bacillus
BT22, and B. subtilis BT23 showed inhibitory activity against several pathogenic
species of Vibrio [40]. They reported that B. subtilis BT23 exhibits a relatively higher
inhibitory activity than the other two Bacillus BT21 and Bacillus BT22. Moreover
B. subtilis BT23 was shown to inhibit the growth and proliferation of 112 isolates
of Vibrio spp. consisting of V. harveyi (39 isolates), V. anguillarum (24 isolates),
V. vulnificus (30 isolates), and V. damsela (19 isolates) which were obtained from
P. monodon culture hatcheries and ponds. The growth and proliferation of pathogenic
V. harveyi was inhibited by B. subtilis BT23 culture inoculated at a preliminary level
of 105–109 cfu ml1, whereas lower concentrations of B. subtilis BT23 (105 and
107 cfu ml1) allowed early growth and proliferation followed by a decrease in the
total viable counts of V. harveyi. Co-culture experiments demonstrated that the
growth and proliferation of V. harveyiwas controlled under in vitro conditions when
the concentrations of B. subtilis BT23 were increased. Experiments of cell-free
Figure 1.
(a) Light micrograph of uninfected Bacillus sp.; (b) TEM micrograph showing phages on the surface of the
infected Bacillus. (c) TEM micrograph of phage-lysed bacterial cell. (d) TEM micrograph of uninfected Vibrio
cells. (e) TEM micrograph of phage-infected Vibrio cell. (f) TEM micrograph of phage-lysed Vibrio cell.
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extracts of Bacillus subtilis BT23 established the inhibitory effects on the growth and
proliferation of V. harveyi in liquid culture under aerobic conditions. The inhibitory
efficacy was higher in B. subtilis BT23 cell-free extracts of 108 cfu ml1 and low in
104 cfu ml1. Cell-free extracts of Bacillus subtilis BT23 initially could not limit the
growth and proliferation of V. harveyi for 2 days, and afterward the growth and
proliferation of V. harveyi was extremely inhibited when compared with the growth
of V. harveyi without B. subtilis BT23. The studies on the probiotic treatment V.
harveyi-infected P. monodon revealed a substantial reduction in the mortality of
shrimp which were treated with B. subtilis BT23 strains under in vivo conditions.
The cumulative mortality of V. harveyi post-infection and probiotic B. subtilis BT23-
untreated P. monodon was 50% on the ninth day and 100% on the seventeenth day
of post-infection. In contrast, in the probiotic treatment groups, the cumulative
mortality of shrimp was 10% in the combined treatment after 5 days post-infection.
Long-term and short-term treatments of V. harveyi-infected P. monodon with B.
subtilis BT23 showed a decrease in cumulative mortality of 32 and 60%, respec-
tively. In control groups of V. harveyi-uninfected P. monodon, there was no mortal-
ity. The growth of pathogenic V. harveyi was inhibited by nonpathogenic B. subtilis
BT23 under in vivo and in vitro conditions. Co-culture experiments showed that the
inhibitory activity of B. subtilis BT23 increased with increasing density of the
antagonist. A high concentration of B. subtilis BT23 (antagonist) was essential to
obstruct the growth and multiplication of V. harveyi in the co-culture experiments.
The antagonist required being present at significantly higher levels than the patho-
gen, and the degree of inhibition increased with the level of antagonist. During the
co-culture, 107/108 cfu ml1 was required to inhibit the growth of the pathogen
V. harveyi. Therefore, a potential probiotic co-culture must either be supplied on a
regular basis or be able to colonize and multiply on or in the host. A similar control
of pathogenic Vibrio in fish and shellfish, by the use of nonpathogenic bacterial
strains and disease prevention, has received much attention during the last decade
[42, 43, 56, 81]. Purification and characterization of the antibacterial substances
from the host bacteria and the phages could help to understand the mechanism of
antibacterial activity of Bacillus and other strains. Probiotic treatment offers a very
promising alternative to the use of antibiotics in fish and shrimp aquaculture.
Further study is needed to elucidate the exact mode of action of the observed
beneficial effects of the probiotics and to understand the possibilities and limita-
tions of microbial control in aquaculture.
2.10.1 Long-term storage of phages
The usefulness of a phage lysate preparation and treatment method adopted for
long-term storage of phages was elucidated in a study that demonstrated the infec-
tivity of the phages of Vibrio spp. that remained unaffected with chloroform and
DMSO treatments and storage at 40°C for 30 days [37–39, 41]. Similarly, phages
were shown to be highly stable under normal storage conditions and also stable in
NaCl and MgSO4 due to its stabilizing effect. Substantial amounts of viable phages
were reported to occur even after storage even in distilled water. Phage isolates
were found to be stable upon storage at 4°C, and a rapid loss of phage infectivity
was encountered with repeated freezing and thawing at 70°C. Bacillus phage was
stable to a 1-hour exposure to chloroform, indicating that it probably does not
contain chloroform-soluble lipids and lipoproteins. V. vulnificus phage infectivity
could not be inhibited with trypsin, protease, and ribonuclease treatments, while
the infectivity of the Vibrio phages was inhibited with lysozyme and SDS treat-
ments, perhaps demonstrating that the enzyme has interfered with the adsorbing of
the phages [38, 39, 41]. The enzymatic treatments and inhibition of phage
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infectivity of several phages were reported. Proteinase K treatment could not alter
the adsorption ability of phage particles. These studies show that binding of the
phages to its host cell membrane is the first step of lytic cycle and this can be an
irreversible mechanism, and a similar mechanism may exist in the infection of
vibriophages as the infectivity of the phages were inhibited by lysozyme and SDS
treatments. Treatment with 1% SDS did not affect the adsorption ability of phage
particles. Similarly Mycoplasma arthritidis virulent 1 (MAV1) phage infectivity was
reported to be unaffected by treatment with Triton X-100 and was resistant to
nonionic detergents. Vibrio phages were found to be fairly resistant to chloroform
[46, 101]. Further studies on the proteins and lipids of V. vulnificus phages may help
us to understand their role in the life cycle and infectivity of phages. V. vulnificus
phages survived 100% at pH 7 and exhibited infectivity, while none of the phages
survived at extreme pH conditions (pH 3 and pH 12) [41]. V. harveyi phages were
inactivated at pH 3 or less and at pH 12 or greater. In contrast, VPP97 phage was
totally inactivated at pH below 5 or over 10. All V. vulnificus phages from the shrimp
Penaeus monodon exhibited optimal survival at 37°C, but infectivity occurred, and
plaques were observed up to a maximum temperature of 50°C [41]. JSF9 phage was
shown to be stable at a temperature below 37°C, and the phages were rapidly
inactivated above 50°C temperature. V. parahaemolyticus phage (VPP97) has been
shown to be stable up to a temperature of 65°C and was totally inactivated at 70°C
[41, 54, 58, 77, 101]. Phages were reported to survive extremes of temperature up to
95°C [54]. Phages, viz. T-ϕD0, T-ϕD2S, T-ϕHSIC, and T-ϕD1B, exhibited a latent
period ranging from 90 to 180 min [77]. The results have clearly shown the physi-
cochemical parameters are very important for the survival and infectivity of phages
[37, 38, 46, 49]. Additional studies related to infectivity, stage specific expression of
proteins, and specific effects of the purified phage proteins are needed to better
understand their functions and applications in the control and process of infectivity
of V. vulnificus phages.
2.10.2 Phage therapy for vibriosis in shrimp
Phage therapy is a re-emerging field, and the bacteriophages represent potential
biocontrol agents for the control of virulent and drug-resistant bacteria [19, 23–73].
However the use of phage therapy in shrimp is still in its early years, and these are
highlighted especially the need for using more than one kind of bacteriophage in
aquaculture to evade development of bacterial resistance [47–49, 58–60]. Phage
therapy has been effectively used to protect against Vibrio diseases in a shrimp and
prawn hatchery. Inhibitory effects of bacteriophages against shrimp pathogenic
Vibrio spp., efficacy of potential phage cocktails against Vibrio harveyi and closely
related Vibrio species isolated from shrimp, morphological characterization and
biocontrol effects of Vibrio vulnificus phages against vibriosis in the shrimp, and a
phage therapy in aquaculture system have been described [37–39, 41]. Four new V.
vulnificus phages were detected from shrimp aquaculture system, named VV1, VV2,
VV3, and VV4 [39]. All lytic V. vulnificus phages belonged to Tectiviridae family
with typical double-layered elongated icosahedral head and tailless morphology
[39, 101]. Lytic V. vulnificus phages which infect other Vibrio isolates were further
characterized for long-term storage by enzyme treatment, organic solvent treat-
ment, detergent treatment, pH stability, temperature stability, and agar bioassay
method and one-step growth experiment. The infectivity, growth, and multiplica-
tion of VV1, VV2, VV3, and VV4 phages were unaffected by the treatment effects
of chloroform, acetone, ethyl alcohol, methyl alcohol, ribonuclease (RNase), tryp-
sin, protease, and Triton-X100. The phages (VV1–VV4) were inactivated
completely with temperature (over 60°C), pH (below 3 and above 12), and
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lysozyme and sodium dodecyl sulfate (SDS) treatment. One-step growth experi-
ments indicated a latent period of 3 h and a burst size at 37°C. Agar bioassay method
indicated that the percentage inhibition of the bacteria Vibrio was 75 (VV1) and 70
(VV2, VV3, and VV4), respectively. V. vulnificus phages had a broad lytic spectrum
and potential biocontrol of luminous vibriosis in the shrimp aquaculture system
[39, 41, 101]. The lytic Vibrio vulnificus phages may provide a better understanding
of phage-host interactions and development of phage therapy in the aquaculture
system. Besides, 12 V. harveyi phages showing broad host ranges were recovered
from seawater samples. Further, some of the phages of ϕH17-5c, ϕH17-7b, ϕH17-8b,
and ϕH17-9b were reported to show inhibitory activity against V. harveyi based on
various tests, viz. heat stability, chloroform stability, adsorption rate, and one-step
growth experiment [58]. A bacteriophage of Vibrio harveyi was secluded from
shrimp farm water from the West coast of India and demonstrated to exhibit a
broad lytic activity against V. harveyi isolates [48, 49]. V. harveyi-infected larval
shrimp exhibited a higher rate of survival in the presence of the bacteriophage than
the uninfected control larval shrimp. Bacteriophage treatment of the vibriosis of
shrimp in hatchery tanks enhanced the survival of the V. harveyi-infected shrimp
larvae and reduced the bacterial counts [50–55, 57, 58]. Bacteriophages secluded
from a shrimp hatchery and farmed P. monodon samples exhibited lytic activity
against V. harveyi and also controlled the population of V. harveyi and improved the
survival of Penaeus monodon larvae [41, 48–52, 58]. Purified bacteriophages
exhibited lytic activity, indicating they are appropriate for phage therapy applica-
tion [29, 53]. A few bacteriophages that infected V. harveyi in a shrimp hatchery
were unable to control the outbreak of luminescent vibriosis disease in a shrimp
culture system [75]. The potential of the bacteriophages of Vibrio harveyi was
reported to control population of pathogenic Vibrio harveyi in a hatchery setting
[48]. In a set of laboratory experiments, post-larval Penaeus monodon was exposed
to 106 cfu ml1 cells of Vibrio harveyi and was treated with 100 ppm phage which has
led to a drastic reduction of Vibrio harveyi counts with 86% survival of the infected
larvae, while the survival of the phage-untreated larvae was 25%. In the antibiotic
(oxytetracycline 5 ppm, kanamycin 100 ppm/day)-treated hatchery tanks, an initial
reduction of luminous bacterial counts was shown, and after 48 h the bacterial
count increased to 106 ml1, showing the luminous vibriosis and mortality of the
nauplii of Penaeus monodon with 40% larval survival. In contrast, in the
bacteriophage-treated tank, the larval survival was 86%, and the survival rate in the
control tank was only 17% [48]. The presence of V. mimicus (15 isolates), exhibiting
a typica profile of Vibrio [49] (two isolates), was obtained from diseased tissues of
penaeid shrimp. A prominent occurrence of V. harveyi, V. furnissii, V. mimicus, V.
damsela, and V. anguillarum in the hatchery tank water besides MBV- and WSSV-
uninfected P. monodon, sea sediment, seawater, and shrimp culture pond sediment
and shrimp culture pond water has been recorded [30, 53]. Vibriosis (V.
alginolyticus)-associated mortality has been recorded in several invertebrates such as
Penaeus monodon andMacrobrachium rosenbergii. Phage therapy has been shown to
inhibit the growth and multiplication of V. harveyi, V. parahaemolyticus, and V.
anguillarum. Bacteriophages belonging to Siphoviridae family are positive to control
Vibrio species as the Siphoviridae phages are considered to have a specific host range
consisting of species of Vibrio harveyi, Vibrio parahaemolyticus, and Vibrio
campbellii [41, 44, 46, 48–53, 58, 60, 69]. A lytic phage PW2 was obtained from
shrimp pond water in Songkhla Province, Thailand, and the morphological charac-
teristics of the phage consisted of an icosahedral head and a long noncontractile tail
categorized under the order Caudovirales and family of Siphoviridae. The phage
PW2 showed lytic properties against Vibrio harveyi [52]. Most of the Vibrio harveyi
phages were found to be siphophages [25, 26, 29, 41, 51]. However, Vibrio harveyi
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phages which were from other families such asMyoviridae and Podoviridae were
also reported [41, 51]. Selection of a suitable bacteriophage or a cocktail of phages is
the key issue in the success of phage therapy of Vibrio species. Moreover phage
cocktails have been demonstrated to be more effective than individual phages in
treatment of Vibrio infection. By making a phage cocktail, it would become easier to
treat a wide range of drug-resistant bacterial infections [58, 68]. Moreover phage-
resistant mutants are exceptional, and hence the use of a multiphage therapy might
decrease the resistance mechanism [61–65, 81, 82]. The limitations of the use of
bacteriophages have been recognized, and the phages cannot be used if they (1)
have toxin gene insertion; (2) have endotoxin release due to their lytic effect on the
host bacterial cells; (3) have a risk of genetic material exchange, i.e., transduction or
phage conversion; (4) have propagation and continuous maintenance; (5) have
development of anti-bacteriophage bodies against them; (6) have the cost temper-
ate phages contributing to bacterial virulence; (7) have emergence of phageresistant
bacteria; (8) have disease outbreak of unknown bacteria when phage specificity is a
problem; and (9) are continuously removed by the immune system [80–82].
Vibriophages themselves may have some protective effects though they can be
candidates as therapeutic agents in bacterial infections in the aquaculture system,
and therefore there is a need to be further investigating them in their natural
environment. Future work may involve obtaining consistent credible results which
can substantiate the application of bacteriophages to control vibriosis in shrimp and
extending such research to other organisms. The usefulness of phage therapy to
control microbial infections that occur in dissimilar organisms at various stages of
from eggs to brood stock, as well as in laboratory, tanks, or field applications, was
shown in experiments made with shrimp larvae, showing a promising potential for
phage therapy [46]. The life-saving antibiotics and the new-generation antibiotics
cannot be used in aquaculture, and therefore the bacteriophages have the natural
advantages and potential to be used in management of the vibriosis in aquaculture.
2.10.3 Phage therapy in lobsters
Significant (71%) mortalities of larval, post-larval, and adult lobsters were
caused by shell diseases where Vibrio spp., besides Pseudomonas, and Aeromonas
have also been isolated. A strain of Vibrio owensii (DY05) was isolated from an
epizootic in aquaculture-reared larval phyllosomas of the ornate spiny lobster
Panulirus ornatus [10–12, 55]. Bacteriophage therapy was one of the techniques that
controlled and removed the pathogenic Vibrio spp. from the larval cultures of the
tropical rock lobster, Panulirus ornatus. V. harveyi has been found to be associated
with diseases in spiny lobster [55].
Crothers-Stomps and colleagues [55] demonstrated that from eight bacterio-
phages (six phages belonged to the family Siphoviridae, and two belonged to the
familyMyoviridae), only one bacteriophage from the family Siphoviridae was shown
to exhibit a clear lytic activity against V. harveyi with no apparent transducing
properties. They have identified the occurrence of phage resistance as a major
constraint to the use of phage therapy in aquacultures as the pathogenic bacteria
were not completely eliminated [29, 41], and a similar approach on other phages is
essential for understanding of the mechanism of development of phage resistance.
2.10.4 Diseases of Macrobrachium rosenbergii (DeMan)
Bacterial and fungal diseases are accountable for the high mortality and pro-
found economic loss encountered in the giant freshwater prawn M. rosenbergii
aquaculture industry [19–21]. Vibriosis (V. alginolyticus)-associated mortality was
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recorded inM. rosenbergii [19–21]. They have shown the occurrence of a very high
load of total heterotrophic bacterial count and a total presumptive Vibrio count in
the 11 different larval stages ofM. rosenbergii, whereas the total heterotrophic
bacterial count was higher in the larval tank water throughout the cycle of theM.
rosenbergii larval culture. The control treatment methods for the vibriosis consisted
of chlorination, application of antibiotics, UV radiation alone, and a combination of
sequential treatments starting from chlorination (2 ppm) followed by sand filtra-
tion, dechlorination, UV radiation (10 s) and microfiltration (5 μm size), and the
sequential treatments inM. rosenbergii, and these had resulted in the gradual reduc-
tion of V. alginolyticus counts, and these were shown to be the best methods to
control the pathogenic bacterial population in hatcheries of freshwater prawn
M. rosenbergii. Antimicrobial resistance profile of Vibrio species isolated from the
hatchery system ofM. rosenbergii has been reported [19–21]. Vibriosis of M.
rosenbergii can be controlled through phages φSt2 and φGrn1 of V. alginolyticus from
live feed A. salina [97–99].
2.10.5 Diseases of crabs
Shell diseases are caused by chitinolytic bacteria which were encountered in
English prawn Palaemon serratus; American lobsters Homarus americanus; penaeid
shrimp; and king crabs, Paralithodes camtschaticus and Paralithodes platypus; and the
tanner crabs Chionoecetes tanneri are affected by rust diseases caused by chitin-
destroying bacteria [7]. Biocontrol method against the infection of V. anguillarum
for rearing the swimming crab larvae Portunus trituberculatus in the aquaculture
water has been described [94–96]. A bacterial strain PM-4 Thalassobacter utilis
isolated from a crustacean culturing pond was shown to inhibit the growth of
pathogenic Vibrio anguillarum in seawater and to improve the growth of larval crab.
The cells of the bacterial strain PM-4 T. utilis were cultured in a large quantity and
were added daily for 63 of seawater used for culturing larval crab Portunus
trituberculatus. Initial V. anguillarum bacterial density in the crustacean culture
water was 106 cells ml1, while at the crab larval growth stage zoea II, the bacterial
density was found to increase to more than 107 cells ml1 and reduced the patho-
genic V. anguillarum bacteria to 106 cells ml1. When the bacterial strain PM-4
Thalassobacter utilis dominated the bacterial populations, the numbers of patho-
genic bacteria Vibrio spp. were reduced or could not be detectable in seawater. The
growth and production of the larval crab P. trituberculatus were found to be
increased by the addition of the bacterial strain PM-4 to the culture water. Investi-
gations on the bacteriophages and phage therapy specific for aquaculture of crabs
are desirable.
2.10.6 Phage therapy for vibriosis of Artemia salina
The occurrences of V. harveyi, V. furnissii, V. mimicus, V. damsela, and V.
anguillarum in the nauplii of Artemia and the presence of V. harveyi and V. mimicus
in the Artemia-reared water have been recorded [12, 18, 22, 39]. A prominent
occurrence of Vibrio in the Artemia nauplii, Artemia-reared water, egg samples,
hatchery tank water besides MBV- and WSSV-uninfected P. monodon, sea sedi-
ment, seawater, and shrimp culture pond sediment and shrimp culture pond water
was recorded. Vibriosis (V. alginolyticus)-associated mortality has been recorded in
several invertebrates such as Penaeus monodon andMacrobrachium rosenbergii
[18–21, 34, 97–99]. Vibrio species normally reside in the live feed organism such as
Artemia salina which serves as means of carrying and establishing the bacteria into
the hatchery and aquaculture system where V. alginolyticus has been reported as the
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prevailing member of the cultivable bacterial community of Artemia. There are a
number of studies indicative that Artemia nauplii are vectors of potentially harmful
bacteria such as Vibrio spp. Goulden et al. [12] reported that Vibrio owensii (DY05)-
infected Artemia (brine shrimp) was responsible for 84–89% mortality of the
aquacultured larval phyllosomas of the ornate spiny lobster Panulirus ornatus, and
an understanding of the infection processes can help to improve targeted biocontrol
strategies. The existing disinfection techniques such as filters, chlorination, ozone,
UV, etc. could not prevent the occurrence of bacterial pathogens in the hatcheries
and may perhaps help in the growth, proliferation, and multiplication of the
opportunistic pathogen application of broad-spectrum antibiotics in the feed and
hatchery water which has been the most natural strategy to control bacterial infec-
tions. The practice of applying antibiotics in aquaculture has become unattractive as
many important bacterial pathogens belonging to the genera Aeromonas and Vibrio
evolve antibiotic resistance. The excessive and indiscriminate use of antibiotics has
resulted in the development of multidrug-resistant bacterial strains and public
health problems. In shrimp hatcheries, the use of bacteriophages that infect bacteria
is an alternative method to selectively eliminate their bacterial hosts while leaving
normal microbiome unaltered. Phage therapy has been shown to inhibit the
growth and multiplication of V. harveyi, V. parahaemolyticus, and V. anguillarum
[39, 97–99].
2.10.7 In vitro lytic effect of phages φSt2 and φGrn1 on Vibrio strains of Artemia salina
In vitro cell lysis experiment of phage (a) φSt2 and (b) φGrn1 was carried by
infecting the fresh cultures of the host bacteria V. alginolyticus strain V1 which was
collected from live feed A. salina culture [97–99]. The lysis of the host bacteria V.
alginolyticus strain V1 grown in TCBS was proportional to the multiplicity of infec-
tion (MOI) (which is defined as the ratio between the number of viruses in an
infection and the number of the host cells which can be resolved by correcting the
relative concentration of virus and host) used. The lowest (MOI = 1) showed no
effect, while the highest (MOI = 100) showed a complete inhibition of bacterial
growth. The phages were also tested in vitro against 12 different bacterial isolates
grown in TCBS which originated from live feed A. salina culture. A phage mixture
of φSt2 and φGrn1 at MOI = 100 was shown to affect the growth of all 12 bacterial
strains tested, and the study showed that in all cases, there was a delay in the
exponential phase, and even when the cultures reached a plateau of growth, the
density of phage-treated bacteria was lower than their corresponding controls.
2.10.8 In vivo efficacy of phages on the vibriosis of A. salina culture
The effect of the phage mixture (φSt2 and φGrn1 at MOI = 100) was examined
by administrating the phages in vivo in the live prey cultures of A. salina. After 4 h
of administration of the phage mixture, Vibrio count was not altered in the phage-
untreated control cultures, while the Vibrio count drastically reduced in the phage-
treated cultures of A. salina [97]. The total Vibrio counts in the phage-treated
cultures of A. salina was 5.3  103  3.1  103 cfu ml1, which was 93% lesser than
that of the initial total Vibrio counts. The φSt2 and φGrn1 phages affected the
growth of a range of Vibrio spp. and exhibited lytic activity in eight different V.
alginolyticus strains [97]. The phages also exhibited infection in 10 out of the 25
Vibrio strains (40%) tested and lysis in bacterial strains such as V. harveyi and V.
parahaemolyticus species and were known to affect the growth of several strains of
bacteria V. harveyi strains isolated from an Artemia live feed organism. A broad host
range of φSt2 and φGrn1 phages indicated the occurrences of a very similar host
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structures as receptors, viz. LPS phage receptors on the outer membrane of many of
Gram-negative bacteria and the genetic similarity contributing to this broad lytic
spectrum of the phages φSt2 and φGrn1 phages which exhibited a strong lytic effect
against V. alginolyticus-type strain DSM 2171 [98]. The bacteriophages, φSt2 and
φGrn1, are having a broad host range, and such biological attributes make them the
potential candidates for phage therapy application, and these advocate that phage
therapy can be an alternative to antibiotics in aquaculture. The phages, viz. φSt2
and φGrn1 and a giant bacteriophage pVa-21, can effectively be used in the biolog-
ical control of pathogenic Vibrio species in marine hatcheries [97–99]. These studies
indicate the potential applications of the phages for various purposes outside aqua-
culture, and further research on the specificity, phage-host interactions, proteo-
mics, and genomics of phages are needed to establish their usefulness and
utilization. Efficacy of phage therapy was shown to prevent mortality of the vibrio-
sis-infected brine shrimp Artemia franciscana [97–99]. Application of single-type/
cocktails of phages against V. parahaemolyticus- and V. harveyi-infected cysts and
nauplii Artemia franciscana showed a drastic improvement in the survival rate
(from 85 to 89%) and hatching success (100% in both cases) in groups treated with
phages, whereas the control groups exhibited a survival rate of 40–50% and hatch-
ing success (50%). These studies indicate that the phage cocktails offer an alterna-
tive to chemotherapeutic agents and can be used in brine shrimp production.
3. Conclusions
The callous use of antibiotics against bacterial diseases in the culture of crusta-
ceans in the aquatic system has led to the development of antibiotic-resistant bac-
terial infections which can be a serious threat to all life forms and public health, and
the phage therapy may help to overcome such complex problems. Control of bacte-
rial diseases in the future may depend on development of novel drugs, innovative
approaches, and management practices to minimize the risk of introduction of
infectious agents into aquaculture systems and to reduce predisposing factors. The
occurrences of lytic bacteriophages of Bacillus spp./Vibrio spp. as well as their
efficacy were established. Phage therapy has been shown to inhibit the growth and
multiplication of many different pathogenic bacteria, viz. V. harveyi, V.
parahaemolyticus, V. alginolyticus, V. furnissii, V. mimicus, V. damsel, and V.
anguillarum, and promote better survival and production of the crustaceans in
aquaculture. Infected live feed Artemia is responsible for the establishment of the
bacterial infections in the hatchery and aquaculture system causing mass mortality
of the larval crustaceans in culture, and such bacterial infections can be controlled
through lytic phages, viz. ϕH17-5c, ϕH17-7b, ϕH17-8b, and ϕH17-9b from V.
harveyi; phages VV1, VV2, VV3, and VV4 from V. vulnificus; and φSt2 and φGrn1 of
V. alginolyticus of A. salina. However development of specific cocktails of phage
therapy for aquaculture of crabs, prawns, lobsters, and crabs is desirable. The phage
therapy is an ideal method for the control of microbial infections that occur in
dissimilar organisms at various stages from eggs to brood stock as well as in labora-
tory, tanks, or field applications, and extending such research to other organisms
could be one of the valuable strategies, to provide evidences and validate the
usefulness and therapeutic potential of the phage therapy. An understanding of the
infection processes, phage resistance, the efficacy of phage therapy on the targeted
pathogens, and their impact on the normal microbiome can help to improve bio-
control strategies. The potential applications of the phages for various purposes
outside aquaculture and further research on the specificity and phage-host interac-
tions are needed to establish their usefulness and exploitation. Future work may be
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carried out on the intricacies of phage lifestyles and their dynamics in natural
systems, genome and viriomes, proteome analysis, genes coding for their proteins,
and DNA polymerase phylogeny, which can help us in identifying novel methods of
phage-host interaction and in understanding the way in which phages control their
hosts. The use of probiotic organisms and phage therapy in crustacean aquaculture
is found to be safe for the consumer of shrimp, and therefore a scientific rational
approach is needed to evolve guidelines for phage therapy/probiotic applications in
aquaculture and for their use and safety.
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